

Current studies enrolling at Cedars-Sinai

Disease	Study Drug / Device	Study Title	Criteria	Contact
HCV				
HCV-partial-responder/relapser	Boceprevir (INF + RBV + Protease inhibitor vs IFN + RBV + Placebo)	A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin. Double-blind, placebo-controlled. (P05685)	Genotype 1, partial-responder/relapser	Dawn Rago
HCV-naïve	ANA598-504 (INF + RBV + polymerase inhibitor vs IFN + RBV)	A Phase 2, Randomized, Double Blind, Placebo-controlled, Ascending Multiple Dose Trial of the Safety, Efficacy and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment Naïve Genotype 1 Patients with Chronic Hepatitis C Infection	Genotype 1, naïve	Grace Chee
HCV-naïve	IDX184 Nucleoside metabolite (potent polymerase inhibitor) + IFN+RBV	A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin in Subjects with Genotype 1 Chronic Hepatitis C Infection (IDX-08C-004)	Genotype 1, naïve	Jennifer Strange
HCV-naïve	Intron A via Medtronic Paradigm Infusion pump + RBV vs PegIntron + RBV	A Phase II Multicenter, Randomized, Open-Label, Active-Control, Dose-Ranging Study of Interferon alfa-2b Given Via Continuous Subcutaneous Infusion in Subjects with hepatitis C Virus Genotype 1 Infection.(COPEHCV)	Genotype 1, naïve	Alana Steinsiek
HCV-naïve	Remicade (Remicade + IFN+ RBV vs Placebo + IFN+ RBV)	Double Blind, Placebo-controlled: Infliximab (REMICADE) as an adjunct to pegylated-interferon alfa-2b (PEG-INTRON) and Ribavirin (REBETOL) in the treatment of hepatitis C virus infection (genotype 1) (C0168X98)	Genotype 1, naïve	Alana Steinsiek
HBV				
HBV all	coming soon	NIH study		Sandy Leong
Platelets				
HCV with thrombocytopenia	Eltrombopag + SOC vs Placebo + SOC	Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (Enable1 103922, Enable 2 108390)	All genotypes, compensated cirrhotics with low platelets (<75,000); Naïve, nonresponder and relapser	Jennifer Strange
HCC				
Advanced HCC	Mapatumumab (Sorafenib + Mapatumumab vs Sorafenib + Placebo)	A Two-Stage, Multi-Center, Open-Label Study of Mapatumumab ([HGS1012], A Fully-Human Monoclonal Antibody to TRAIL-R1) in Combination with Sorafenib as a First Line Therapy in Subjects with Advanced Hepatocellular Carcinoma	Advanced, non-resectable, non-transplantable HCC	Alana Steinsiek
Advanced HCC	Linifanib vs. Sorafenib	An open-label, randomized phase 3 study of the efficacy and tolerability of Linifanib (ABT-869) versus Sorafenib in subjects with advanced HCC	Advanced, non-resectable, non-transplantable HCC	Alana Steinsiek

Current studies enrolling at Cedars-Sinai

OLT				
HIV Transplant	long term feasibility and outcome study of liver transplantation in HIV+ patients	Solid Organ Transplantation in HIV (HIV TR)	HIV+ w/ cirrhosis, eligible for transplant	Sandy Leong
Fulminant Hepatic Failure				
Acute on Chronic Hepatitis	ELAD (Artificial Liver) + SOC vs SOC alone	Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects with Acute on Chronic Hepatitis (VTI-206)	Acute on chronic hepatitis	Alana Steinsiek

Contact Information:

Alana Steinsiek	310-423-3949	alana.steinsiek@cshs.org
Jennifer Strange	310-423-2743	jennifer.strange@cshs.org
Dawn Rago	310-423-9545	dawn.rago@cshs.org
Grace Chee	310-423-5461	grace.chee@cshs.org
Sandy Leong	310-423-5453	sandy.leong@cshs.org
Teresa DiDiego	310-423-5050	teresa.didiego@cshs.org
Martin Briseno	310-423-7837	martin.briseno@cshs.org